Showing 4891-4900 of 9741 results for "".
- FDA Approves Lilly's Taltz for Label Update to Treat Psoriasis Involving the Genital Areahttps://practicaldermatology.com/news/fda-approves-lillys-taltz-for-label-update-to-treat-psoriasis-involving-the-genital-area/2457755/The FDA has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area. Eli Lilly and Company's Taltz is the first treatment FDA approved for moderate-to-severe plaque psoriasis that includes such data in its label. Taltz was
- FDA Approves Tafinlar + Mekinist for Adjuvant Treatment of BRAF V600-Mutant Melanomahttps://practicaldermatology.com/news/fda-approves-tafinlar-mekinist-for-adjuvant-treatment-of-braf-v600-mutant-melanoma/2457786/The FDA has approved Novartis' Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. The FDA
- RealSelf Names Tanja Omeze Chief Marketing Officerhttps://practicaldermatology.com/news/realself-names-tanja-omeze-chief-marketing-officer/2457808/Ms. Tanja Omeze is RealSelf’s first ever chief marketing officer (CMO). As CMO, Ms. Omeze leads global marketing to increase awareness, engagement and connections among and between consumers and medical aesthetic professionals. Ms. Omez
- YouTube AD Videos Unreliablehttps://practicaldermatology.com/news/youtube-ad-videos-unreliable/2457835/Perhaps no surprise to dermatologists, new research reveals that one-third of YouTube videos about atopic dermatitis contain misleading information. That’s according to researchers from the University of Texas Health Science Center in Houston who reviewed 128 YouTub
- ALASTIN Adds to Board of Directorshttps://practicaldermatology.com/news/alastin-adds-to-board-of-directors/2457837/Ann Rhoads and Elisabeth Sandoval are now members of ALASTIN Skincare, Inc’s Board of Directors. Ms. Rhoads is a healthcare finance executive with more than 25 years of experience which includes roles as Chief Financial Officer of
- Colorescience Adds to Board of Directorshttps://practicaldermatology.com/news/colorescience-adds-to-board-of-directors/2457838/David Olsen and Ty Stiklorius are joining Colorescience’s Board of Directors. David Olsen is the Chief Executive Officer (CEO) of Cos Bar. Since joining Cos Bar in February 2016, he has worked to grow the company while
- Differin Launches Retinoid Education Weekhttps://practicaldermatology.com/news/differin-launches-retinoid-education-week/2457848/Differin® has launched Retinoid Education Week to educate the more than 50 million Americans with acne about how retinoids can be used to treat their condition. Part of Nestlé Skin Health’s acne franchise, Differin is new to the over-the-counter acne category. However, retinoids
- Dermira: Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpointshttps://practicaldermatology.com/news/dermira-two-phase-3-trials-evaluating-olumacostat-glasaretil-in-patients-with-acne-vulgaris-did-not-meet-co-primary-endpoints/2457852/Dermira, Inc.'s investigational treatment olumacostat glasaretil (formerly DRM01) did not meet the co-primary endpoints in its two Phase 3 pivotal trials (CLAREOS-1 and CLAREOS-2) in patients ages nine years and older with moderate-to-severe acne vulgaris. “We are surprised and
- Dr. Jacob Chacko Joins Bonti's Board of Directorshttps://practicaldermatology.com/news/dr-jacob-chacko-joins-bontis-board-of-directors/2457893/Jacob Chacko, MD has joined Bonti’s Board of Directors. Dr. Chacko has served as the Chief Financial Officer of Ignyta, Inc. since May 2014. At Ignyta, he leads multiple functions, including Finance, Accounting, Investor Relations, Communications
- Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in EBhttps://practicaldermatology.com/news/abeona-receives-fda-regenerative-medicine-advanced-therapy-designation-for-eb-101-gene-therapy-in-eb/2457908/The US Food and Drug Administration (FDA) granted the Regenerative Medicine Advanced Therapy (RMAT) designation to EB-101, Abeona Therapeutics Inc.’s gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). “EB-101 is